BioSpace News Archive

Leading school science supplier Carolina Biological Supply Company, announced that this fall teachers of Advanced Placement® science courses at U.S. military-run high schools integrated the latest College Board-aligned resources to teach science with Carolina AP® Kits. Carolina Investigations™ for AP® Kits are specifically designed to meet the goals of the revised AP® curriculum

Technology overcomes limitations of traditional and dual-energy X-Ray imaging, using a world first mobile 14”x17" cassette-sized detector. Reveal™ enables soft-tissue differentiation with a single exposure without motion artifacts

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fourth quarter and fiscal year ended September 30, 2019, following the close of market on Wednesday, December 11, 2019.

Predictive Oncology Inc. announced that it entered into a $15 million common stock purchase and registration rights agreement with Oasis Capital, LLC, a Puerto Rico limited liability company, to purchase from the Company up to Fifteen Million Dollars of the Company’s Common Stock.

BTIG announced today that Camilo Lyon has joined the firm’s Research and Strategy division to launch coverage across the consumer sector, focusing on lifestyle and wellness brands. He will be based in the firm’s New York office, and will report to David Lenchus, Director of Research at BTIG.

Insights Care magazine and online publication has awarded Nautilus Medical the top spot for the Most Advanced Medical Imaging Provider out of 10 finalists for the cover story.

Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next generation, transformative cancer treatments, today announced the completion of its $56 million Series A financing.

Vertical Pharmaceuticals, LLC announced that the Company received notification that the New Drug Application for RVL-1201 for Acquired Blepharoptosis has been filed by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act goal date of July 16, 2020.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of “NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results,” in the international, peer-reviewed journal Neurology:Volume 93, Number 24 (Published ahead of print.)